Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Faries MB;Faries MB; Cochran AJ; Elashoff RM; Thompson JF
  • Source:
    The British journal of dermatology [Br J Dermatol] 2015 Mar; Vol. 172 (3), pp. 571-3.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Extramural; Comment
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE
    • Publication Information:
      Publication: 2023- : Oxford : Oxford University Press
      Original Publication: Oxford [etc.] Published for the British Association of Dermatologists by Blackwell Scientific Publications [etc.]
    • Subject Terms:
      Lymph Node Excision* ; Sentinel Lymph Node Biopsy*; Melanoma/*pathology ; Skin Neoplasms/*pathology; Female ; Humans ; Male
    • Abstract:
      Sentinel lymph node (SLN) biopsy has become a standard procedure for many patients with melanoma and is recommended in numerous national and professional melanoma guidelines. The Multicenter Selective Lymphadenectomy Trial (MSLT-1) confirms earlier large database studies and prospective clinical trials in demonstrating the independent and unequalled prognostic value of the SLN. It also demonstrates the ability of biopsy-directed management to provide effective regional disease control with the least possible morbidity. These benefits are not in question and provide ample justification for the procedure, even without evidence of a survival benefit. However, MSLT-1 also provides strong evidence of a substantial reduction in the risk of melanoma death for patients with intermediate thickness melanomas who harbour occult nodal metastases at the time of presentation. Denying appropriately selected patients with melanoma the opportunity to undergo SLN biopsy is no longer reasonable or acceptable.
      (© 2015 British Association of Dermatologists.)
    • Comments:
      Comment on: N Engl J Med. 2014 Feb 13;370(7):599-609. (PMID: 24521106)
      Comment on: Br J Dermatol. 2015 Mar;172(3):566-71. (PMID: 25776246)
    • References:
      Br J Dermatol. 2015 Mar;172(3):566-71. (PMID: 25776246)
      N Engl J Med. 2014 May 29;370(22):2149-50. (PMID: 24869726)
      J Surg Oncol. 2004 Jul 1;86(4):212-23. (PMID: 15221928)
      Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3. (PMID: 16135917)
      J Clin Oncol. 2009 Dec 20;27(36):6199-206. (PMID: 19917835)
      Br J Cancer. 2010 Oct 12;103(8):1229-36. (PMID: 20859289)
      Ann Surg Oncol. 2010 Dec;17(12):3324-9. (PMID: 20614193)
      Stat Med. 2011 Mar 30;30(7):709-17. (PMID: 21394747)
      Arch Dermatol. 2011 Apr;147(4):408-15. (PMID: 21173300)
      Biometrics. 2013 Mar;69(1):52-61. (PMID: 23383608)
      Dermatol Surg. 2013 Dec;39(12):1800-12. (PMID: 24299573)
      N Engl J Med. 2014 Feb 13;370(7):599-609. (PMID: 24521106)
    • Grant Information:
      P30 CA016042 United States CA NCI NIH HHS; R01 CA189163 United States CA NCI NIH HHS; P01 CA29605 United States CA NCI NIH HHS
    • Publication Date:
      Date Created: 20150318 Date Completed: 20150512 Latest Revision: 20181202
    • Publication Date:
      20221213
    • Accession Number:
      PMC4437591
    • Accession Number:
      10.1111/bjd.13676
    • Accession Number:
      25776247